318 related articles for article (PubMed ID: 10773013)
1. Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences.
Greenblatt DJ; Harmatz JS; von Moltke LL; Wright CE; Durol AL; Harrel-Joseph LM; Shader RI
J Pharmacol Exp Ther; 2000 May; 293(2):435-43. PubMed ID: 10773013
[TBL] [Abstract][Full Text] [Related]
2. Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate.
Greenblatt DJ; Harmatz JS; von Moltke LL; Wright CE; Shader RI
Clin Pharmacol Ther; 2004 Nov; 76(5):467-79. PubMed ID: 15536461
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects.
Berlin I; Warot D; Hergueta T; Molinier P; Bagot C; Puech AJ
J Clin Psychopharmacol; 1993 Apr; 13(2):100-6. PubMed ID: 8463441
[TBL] [Abstract][Full Text] [Related]
4. Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability.
Evans SM; Funderburk FR; Griffiths RR
J Pharmacol Exp Ther; 1990 Dec; 255(3):1246-55. PubMed ID: 2262904
[TBL] [Abstract][Full Text] [Related]
5. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole.
Greenblatt DJ; von Moltke LL; Harmatz JS; Mertzanis P; Graf JA; Durol AL; Counihan M; Roth-Schechter B; Shader RI
Clin Pharmacol Ther; 1998 Dec; 64(6):661-71. PubMed ID: 9871431
[TBL] [Abstract][Full Text] [Related]
6. Benzodiazepine-receptor ligands in humans: acute performance-impairing, subject-rated and observer-rated effects.
Rush CR; Armstrong DL; Ali JA; Pazzaglia PJ
J Clin Psychopharmacol; 1998 Apr; 18(2):154-65. PubMed ID: 9555600
[TBL] [Abstract][Full Text] [Related]
7. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences.
Greenblatt DJ; Wright CE; von Moltke LL; Harmatz JS; Ehrenberg BL; Harrel LM; Corbett K; Counihan M; Tobias S; Shader RI
Clin Pharmacol Ther; 1998 Sep; 64(3):237-47. PubMed ID: 9757147
[TBL] [Abstract][Full Text] [Related]
8. Selective antagonism of the ataxic effects of zolpidem and triazolam by the GABAA/alpha1-preferring antagonist beta-CCt in squirrel monkeys.
Platt DM; Rowlett JK; Spealman RD; Cook J; Ma C
Psychopharmacology (Berl); 2002 Nov; 164(2):151-9. PubMed ID: 12404077
[TBL] [Abstract][Full Text] [Related]
9. Relative abuse liability of indiplon and triazolam in humans: a comparison of psychomotor, subjective, and cognitive effects.
Carter LP; Griffiths RR; Suess PE; Casada JH; Wallace CL; Roache JD
J Pharmacol Exp Ther; 2007 Aug; 322(2):749-59. PubMed ID: 17502431
[TBL] [Abstract][Full Text] [Related]
10. Discriminative stimulus effects of zolpidem in pentobarbital-trained subjects: II. Comparison with triazolam and caffeine in humans.
Rush CR; Madakasira S; Goldman NH; Woolverton WL; Rowlett JK
J Pharmacol Exp Ther; 1997 Jan; 280(1):174-88. PubMed ID: 8996195
[TBL] [Abstract][Full Text] [Related]
11. Residual effects of zolpidem, triazolam, rilmazafone and placebo in healthy elderly subjects: a randomized double-blind study.
Uemura SI; Kanbayashi T; Wakasa M; Satake M; Ito W; Shimizu K; Shioya T; Shimizu T; Nishino S
Sleep Med; 2015 Nov; 16(11):1395-1402. PubMed ID: 26498242
[TBL] [Abstract][Full Text] [Related]
12. Triazolam and zolpidem: a comparison of their psychomotor, cognitive, and subjective effects in healthy volunteers.
Mintzer MZ; Frey JM; Yingling JE; Griffiths RR
Behav Pharmacol; 1997 Nov; 8(6-7):561-74. PubMed ID: 9832970
[TBL] [Abstract][Full Text] [Related]
13. Dose-dependent EEG effects of zolpidem provide evidence for GABA(A) receptor subtype selectivity in vivo.
Visser SA; Wolters FL; van der Graaf PH; Peletier LA; Danhof M
J Pharmacol Exp Ther; 2003 Mar; 304(3):1251-7. PubMed ID: 12604703
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers.
de Haas SL; Franson KL; Schmitt JA; Cohen AF; Fau JB; Dubruc C; van Gerven JM
J Psychopharmacol; 2009 Aug; 23(6):625-32. PubMed ID: 18635696
[TBL] [Abstract][Full Text] [Related]
15. Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers.
Rush CR; Griffiths RR
J Clin Psychopharmacol; 1996 Apr; 16(2):146-57. PubMed ID: 8690830
[TBL] [Abstract][Full Text] [Related]
16. Differential effects in humans after repeated administrations of zolpidem and triazolam.
Stoops WW; Rush CR
Am J Drug Alcohol Abuse; 2003 May; 29(2):281-99. PubMed ID: 12765207
[TBL] [Abstract][Full Text] [Related]
17. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers.
Otmani S; Demazières A; Staner C; Jacob N; Nir T; Zisapel N; Staner L
Hum Psychopharmacol; 2008 Dec; 23(8):693-705. PubMed ID: 18763235
[TBL] [Abstract][Full Text] [Related]
18. Discriminative stimulus effects of zolpidem in squirrel monkeys: comparison with conventional benzodiazepines and sedative-hypnotics.
Rowlett JK; Spealman RD; Lelas S
J Pharmacol Exp Ther; 1999 Dec; 291(3):1233-41. PubMed ID: 10565847
[TBL] [Abstract][Full Text] [Related]
19. Discriminative stimulus effects of zolpidem in pentobarbital-trained subjects: I. Comparison with triazolam in rhesus monkeys and rats.
Rowlett JK; Woolverton WL
J Pharmacol Exp Ther; 1997 Jan; 280(1):162-73. PubMed ID: 8996194
[TBL] [Abstract][Full Text] [Related]
20. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo.
Greenblatt DJ; Harmatz JS; von Moltke LL; Ehrenberg BL; Harrel L; Corbett K; Counihan M; Graf JA; Darwish M; Mertzanis P; Martin PT; Cevallos WH; Shader RI
Clin Pharmacol Ther; 1998 Nov; 64(5):553-61. PubMed ID: 9834048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
